We are developing innovative cell therapy applications to transform treatment of diseases caused by a dysregulated immune system

Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. Our innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, our flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.

Our  Evolution

Early Technology Development

Sentien’s technology is rooted in pioneering cell therapy research performed by Biju Parekkadan, PhD, at the Massachusetts Institute of Technology and the Center for Engineering and Medicine at Massachusetts General Hospital. Once Dr. Parekkadan realized his new MSC therapy approach had the potential to transform treatment for a range of acute and chronic indications, he joined forces with Brian Miller to co-found Sentien Biotechnologies and develop the technology for clinical use. The company was able to attract experienced scientific and industry leaders to its Clinical and Scientific Advisory Board to help guide the early technology development and translation to the clinic. Sentien was awarded a total of $7 million in non-dilutive funding from the NIH’s Small Business Innovation Research (SBIR) program, and its core IP was granted by the USPTO in 2011.

Key Milestones


Secured seed round of financing

Received Fast Track Phase I/II SBIR grants for Acute Myocardial Infarction (MFI) pre-clinical research


Awarded a Boehringer Ingelheim Golden Ticket to LabCentral, Inc., a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups


Closed a $12M Series A investment round

Submitted IND application for SBI-101 and initiated Phase I/II trial of SBI-101 in patients with acute kidney injury

Released first lot of GMP grade material

Moved to new Headquarters in Lexington, MA

Closed second tranche of Series A financing






Completed low dose cohort enrollment in Phase I/II trial of SBI-101 in patients with acute kidney injury

Presented Phase I/II trial interim analysis at 2019 Cell & Gene Therapy Meeting on the Mesa 






Appointed Rich Ganz as Executive Chairman

Appointed Dr. Allen R. Nissenson as Chief Medical Officer

Submitted IND application for SBI-101 and initiated Phase I/II trial of SBI-101 in COVID-19 patients with acute kidney injury 

Awarded $2.4M contract from DoD and MTEC for the development of a potency assay for MSCs in regenerative medicine products







Completed enrollment of low dose cohort in Ph I/II trial of SBI-101 for COVID-19 patients with acute kidney injury 

Announced partnership with BARDA to evaluate SBI-101 in patients with acute kidney injury associated with sepsis